Business Description
LENZ Therapeutics Inc
NAICS : 541720
SIC : 2834
ISIN : US52635N1037
Total Employee Number:
152Description
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 383.93 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.1 | |||||
3-Year EBITDA Growth Rate | -97.4 | |||||
3-Year EPS without NRI Growth Rate | -88.9 | |||||
3-Year FCF Growth Rate | -146.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 103.09 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.46 | |||||
9-Day RSI | 31.12 | |||||
14-Day RSI | 32.73 | |||||
3-1 Month Momentum % | -29.7 | |||||
6-1 Month Momentum % | -59.22 | |||||
12-1 Month Momentum % | -80.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.4 | |||||
Quick Ratio | 10.26 | |||||
Cash Ratio | 10.01 | |||||
Days Inventory | 834.82 | |||||
Days Sales Outstanding | 5.84 | |||||
Days Payable | 1759.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.1 | |||||
Shareholder Yield % | 0.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.87 | |||||
Operating Margin % | -563.83 | |||||
Net Margin % | -519.3 | |||||
EBITDA Margin % | -562.1 | |||||
FCF Margin % | -416.59 | |||||
OCF Margin % | -413.09 | |||||
ROE % | -48.52 | |||||
ROA % | -45.13 | |||||
ROIC % | -2708.43 | |||||
3-Year ROIIC % | -1785.98 | |||||
ROC (Joel Greenblatt) % | -5997.47 | |||||
ROCE % | -52.58 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.8 | |||||
PB Ratio | 0.63 | |||||
Price-to-Tangible-Book | 0.63 | |||||
EV-to-EBIT | 0.87 | |||||
EV-to-EBITDA | 0.87 | |||||
EV-to-Revenue | -4.91 | |||||
EV-to-Forward-Revenue | 0.46 | |||||
EV-to-FCF | 1.18 | |||||
| Price-to-Net-Current-Asset-Value | 0.64 | |||||
| Price-to-Net-Cash | 0.67 | |||||
Earnings Yield (Greenblatt) % | 114.94 | |||||
FCF Yield % | -56.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LENZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LENZ Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.989 | ||
| EPS (TTM) ($) | -3.6 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 80.01 | ||
| 14-Day RSI | 32.73 | ||
| 14-Day ATR ($) | 0.48241 | ||
| 20-Day SMA ($) | 5.9125 | ||
| 12-1 Month Momentum % | -80.48 | ||
| 52-Week Range ($) | 4.905 - 50.4 | ||
| Shares Outstanding (Mil) | 31.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LENZ Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LENZ Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 114 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 16 days | ||
| General meeting for 2026 | 2026-06-12 10:00 | 6.50 (-1.37%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 16:30 | 10.06 (+2.55%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 10.06 (+2.55%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 08:30 | 11.00 (+2.52%) | ||
| Annual report for 2025 | 2026-03-24 | 11.00 (+2.52%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 11.00 (+2.52%) | ||
| Guidance call for 2025 | 2025-12-04 10:30 | 28.00 (+1.34%) |
Show
Entries
LENZ Therapeutics Inc Frequently Asked Questions
What is LENZ Therapeutics Inc(LENZ)'s stock price today?
The current price of LENZ is $4.93. The 52 week high of LENZ is $50.40 and 52 week low is $4.91.
When is next earnings date of LENZ Therapeutics Inc(LENZ)?
The next earnings date of LENZ Therapeutics Inc(LENZ) is 2026-07-30 Est..
Does LENZ Therapeutics Inc(LENZ) pay dividends? If so, how much?
LENZ Therapeutics Inc(LENZ) does not pay dividend.
Guru Commentaries on NAS:LENZ
No articles.
Press Release
Articles on LENZ Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers